Bristol-Myers Squibb
The $48.2B-revenue (2025, -0.2% YoY) pharma company is betting its survival on a Growth Portfolio that expanded 17% in 2025 — Reblozyl ($2B+), Breyanzi, Opdualag, Camzyos each crossed $1B. AI's role is structural: the 'predict-first' approach runs computational validation before synthesis, and the Terray Therapeutics AI collaboration hit a discovery milestone in December 2025. Six pivotal readouts in 2026 (milvexian, iberdomide, mezigdomide, Arlo-cel, admilparant, RYZ101) will determine whether AI-informed pipeline can replace the imminent revenue cliff.
Scenarios
BMS's Growth Portfolio grew 17% in 2025 while legacy products declined — the transition is working faster than the stock price implies. If just two of the six 2026 pivotal readouts succeed, BMS has the basis for 2028-2030 revenue replacement. Milvexian alone targets atrial fibrillation and stroke prevention — a $20B+ peak market. The Cobenfy Alzheimer's psychosis extension readout could add $2-4B peak revenue in a category where no good options exist.
Eliquis European generic entry began May 2026, triggering faster-than-modeled global revenue erosion on a product generating approximately $3.7B per quarter. US Eliquis generic entry follows in April 2028, then Opdivo European protection ends June 2028 — BMS faces simultaneous loss-of-exclusivity on both blockbusters within an 18-month window, representing $12-15B in combined peak annual revenue. AI Proteins deal ($400M) and Terray collaboration are pre-clinical; no AI-discovered BMS candidate has reached Phase III. The Growth Portfolio's 17% expansion is masking that total 2025 revenue was essentially flat — once LOE hits, that buffer disappears.
Key Factors to Watch
- ●Predict-first AI validates molecules in silico before synthesis
- ●30+ GenAI solutions deployed across R&D, supply, commercial
- ●Six 2026 pivotal readouts test whether AI-informed pipeline delivers
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 5.7 | Neutral | Score 5.8→5.7 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 5.8 | Neutral | Score 6.6->5.8 (are 7->5, dr 5->6, aam 7->6). External research cross-ref: 64% of 2025 revenue faces LOE by decade end, partnership-dependent AI strategy more replicable, Fast Follower maturity without C-suite AI leadership |
| 2026-03-08 | 6.6 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-03-02
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.